Company / Current Assets
Travere Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$437.6M
FY2025
5-year range
$416.7M / $616.8M
FY2021-FY2025
Trend
+5.0%
vs FY2024
Sector context
#127 of 213
Health Care
What the data says
At $438M, Travere Therapeutics, Inc.'s current assets ranks #127 of 213 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $326M in FY2017 to $617M in FY2023.
Based on SEC 10-K filings.
$438M in FY2025 with a 5-year CAGR of +1.3%.
Declined from $617M to $438M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -3.5%
- 5-Year CAGR
- +1.3%
- 10-Year CAGR
- -
Sector benchmark
#127 of 213 in Health CareTop 60% of 213This company $437.6M Sector average $2.5B
▼
-82.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.3%, indicating consistent growth.
- In FY2025, current assets increased 5.0% year-over-year.
- Ranks #127 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $437.6M | +5.0% |
| FY2024 | $416.7M | -32.4% |
| FY2023 | $616.8M | +26.8% |
| FY2022 | $486.4M | -16.5% |
| FY2021 | $582.8M | +42.0% |
| FY2020 | $410.4M | -4.3% |
| FY2019 | $429.1M | -13.4% |
| FY2018 | $495.7M | +52.1% |
| FY2017 | $325.8M | -2.0% |
| FY2016 | $332.4M | +10.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026